George Q. Daley head shot

George Q. Daley, MD, PhD

Dean, Faculty of Medicine, Harvard Medical School
Boston Children's Hospital
Howard Hughes Medical Institute

George Q. Daley, M.D., Ph.D, seeks to translate insights in stem cell biology into improved therapies for genetic and malignant diseases. Important research contributions from his laboratory include the creation of customized stem cells to treat genetic immune deficiency in a mouse model (together with Rudolf Jaenisch), the differentiation of germ cells from embryonic stem cells (cited as a “Top Ten Breakthrough” by Science magazine in 2003), and the generation of disease-specific pluripotent stem cells by direct reprogramming of human fibroblasts (cited in the “Breakthrough of the Year” issue of Science magazine in 2008).... Read more about George Q. Daley, MD, PhD

Ben Ebert headshot

Benjamin L. Ebert, MD, PhD

Brigham and Women's Hospital
Dana-Farber Cancer Institute
Harvard Medical School | Broad Institute

The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies, with a particular focus on myelodysplastic syndromes (MDS). In large-scale genetic analyses of patient samples, the lab has identified somatic mutations that predict prognosis and response to therapies in MDS patients. The also focuses on a pre-... Read more about Benjamin L. Ebert, MD, PhD

Markus Frank, MD

Markus Frank, MD

Associate Professor of Pediatrics and Dermatology, Harvard Medical School

Markus Frank’s laboratory research focuses on the physiological and pathological roles of the P-glycoprotein family of ATP-binding cassette (ABC) multidrug...

Read more about Markus Frank, MD
Boston Children's Hospital
Enders Research Building, Room 507
300 Longwood Avenue
Boston, MA 02115
p: 617-919-2993
David M. Langenau, PhD

David M. Langenau, PhD

Massachusetts General Hospital
Harvard Medical School

Our research focuses on using the zebrafish to better understand human cancer and to develop novel insights into how it is that tumors can be remade following conventional chemotherapeutic intervention. Uncovering the downstream molecular pathways that lead to relapse will be integral to identifying novel drugs for the treatment of cancer.... Read more about David M. Langenau, PhD